| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Profit before tax | -11.3 | -8.6 |
| Net income | -11.3 | -8.6 |
| EPS (diluted, $ a share) | $-0.21 | $-0.17 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: DMAC. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
DiaMedica Therapeutics Inc.: key numbers
- Share price
- $8.38Close, Nov 17
- Market cap
- $452M
- Shares outstanding
- 53.96MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from DiaMedica Therapeutics Inc.
All →DiaMedica Therapeutics Financial Results
DiaMedica Therapeutics reported Q3 2026 financial results and provided clinical updates on its DM199 programs. The company completed enrollment in the first two cohorts of its Phase 2 fetal growth restriction (FGR) trial and surpassed the 200-participant enrollment threshold for its ReMEDy2 Phase 2/3 acute ischemic stroke trial, with an interim analysis expected in Q1 2027.
- Term
- Q3 2026
“During the third quarter and recent weeks, we continued to advance DM199 across each of our clinical programs, including completing enrollment in the first two cohorts of our Phase 2 early-onset fetal growth restriction study and reaching the 200-participant enrollment threshold for the planned interim analysis of ReMEDy2.”
Rick Pauls, President and Chief Executive Officer
“Our clinical programs are providing important opportunities to evaluate the pharmacologic effects of DM199 across pregnancy-related vascular disorders and acute ischemic stroke.”
Julie Krop, MD, Chief Medical Officer